Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.36 USD
-0.05 (-2.07%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $2.37 +0.01 (0.42%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Brokerage Reports
Checkpoint Therapeutics, Inc. [CKPT]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Cosibelimab PDUFA Date December 28; Target Adjusted to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Boosting IO Approach With New Collaboration; BLA Acceptance Expected Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Getting Back to Normalcy; Cosibelimab Could Still Be Approved by Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Looking for CRL Resolution Shortly From CMO and FDA; Thesis Unchanged
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; BLA Resubmission For Cosi In the Works; We Anticipate FDA Approval in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Non-Fundamental CRL a Minor Unfortunate Delay; 2024 Approval Still In the Cards
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Three Near-Term PDUFAs Should Drive Significant Long-Time Coming Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pre-PDUFA Feather in the Cap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosi Continues to Deliver; Longer Term Data Show Durability of Clinical Benefit; PDUFA Janury 3, 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosi Profile Should Drive Commercialization Success; Shares Disconnect Persists; Target Adjusted to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In FDA''s Capable Accepting Hands; Cosi PDUFA Set for January 3, 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosi BLA Filed; We Project Favorable Label For This Disruptive Asset; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Time Is Now to Get Cozy With Cosi as First Endgame Nears; Split-Adjusted Target to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Whole Package; Green Light for Locally Advanced cSCC to Be Included in Cosibelimab BLA Submission in YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosimelibab Also Benefits Locally Advanced CSCC Following Positive Metastatic Pivotal Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pictures Speak Volumes for Cosi Pivotal Data at ASCO; More Data This Month and BLA Not Too Far Off
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosibelimab Clears Key Regulatory Hurdle in Europe; BLA Submission on Track for YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Focus is on Upcoming Cosibelimab BLA and Ongoing BD Activities; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Cosibelimab BLA Submission by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pazdur Grumblings Still Place Checkpoint''s Assets Favorably in the Global Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J